Methylphenidate treatment of adult male prison inmates with attention-deficit hyperactivity disorder: randomised double-blind placebo-controlled trial with open-label extension
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
Background: Attention-deficit hyperactivity disorder (ADHD) is highly prevalent in prison inmates, but pharmacological treatment has not yet been evaluated in this group. Aims: To evaluate osmotic-release oral system (OROS) methylphenidate in adult male long-term prison inmates with ADHD. Method: Randomised, double-blind, placebo-controlled 5-week trial, followed by 47-week open-label extension in 30 prison inmates with ADHD and comorbid disorders. Primary outcome was level of ADHD symptoms after 5 weeks, evaluated by a masked assessor. Secondary outcomes were self-reported ADHD symptoms, global severity and global functioning throughout the 52-week trial, and post hoc treatment response and numbers needed to treat (NNT) (trial registration: NCT00482313.) Results: Treatment significantly improved ADHD during the trial (P<0.001; Cohen's d = 2.17), with reduced symptom severity and improved global functioning. The placebo response, cardiovascular measures and adverse events were non-significant; the NNT was 1.1. Attention-deficit hyperactivity disorder symptoms, global severity and global functioning continued to improve during the open-label extension. Conclusions: Osmotic-release oral system methylphenidate is an effective treatment for adult male prison inmates with ADHD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prevalence and correlates of adult attention-deficit hyperactivity disorder: meta-analysis
Simon, V., Czobor, P., Bálint, S., Mészáros, Á., & Bitter, I. (2009) · British Journal of Psychiatry · doi:10.1192/bjp.bp.107.048827 · Cited by 1,601
Biederman, J. (2000) · American Journal of Psychiatry · doi:10.1176/appi.ajp.157.5.816 · Cited by 1,498 · cited 1×
“3,4 In addition, nearly 80% of adults with ADHD present with at least one comorbid disorder, particularly anxiety disorders, affective disorders, substance use disorder and antisocial personality disorder.”
Lobbestael, J., Leurgans, M., & Arntz, A. (2011) · Clinical Psychology & Psychotherapy · doi:10.1002/cpp.693 · Cited by 1,124 · cited 1×
“Body weight was recorded at baseline and weeks 5, 8, 12, 20, 32, 44 and 52.”
Faraone, S. V., Spencer, T., Aleardi, M., Pagano, C., & Biederman, J. (2004) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000108984.11879.95 · Cited by 404
Spencer, T., Biederman, J., Wilens, T., Doyle, R., Surman, C., Prince, J., Mick, E., Aleardi, M., Herzig, K., & Faraone, S. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2004.11.043 · Cited by 385 · cited 1×
“Based on preliminary findings and previous studies, 14,25,26 the aim was to detect a mean difference of 9 units in the CAARS-O:SV (range 0–54) between groups from baseline until the end-point at week 5.”
Ginsberg, Y., Hirvikoski, T., & Lindefors, N. (2010) · BMC Psychiatry · doi:10.1186/1471-244x-10-112 · Cited by 191 · cited 3×
“Considering the high prevalence of untreated ADHD in prison inmates, 8–10 further research on treatment of prison inmates is warranted to confirm and expand upon our findings.”
Self-citationMedori, R., Ramos-Quiroga, J. A., Casas, M., Kooij, J. J. S., Niemelä, A., Trott, G.-E., Lee, E., & Buitelaar, J. K. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.11.008 · Cited by 186 · cited 1×
“Based on preliminary findings and previous studies, 14,25,26 the aim was to detect a mean difference of 9 units in the CAARS-O:SV (range 0–54) between groups from baseline until the end-point at week 5.”
on behalf of the study group, Rösler, M., Fischer, R., Ammer, R., Ose, C., & Retz, W. (2009) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-008-0845-4 · Cited by 155
Koesters, M., Becker, T., Kilian, R., Fegert, J., & Weinmann, S. (2009) · Journal of Psychopharmacology · doi:10.1177/0269881108092338 · Cited by 142 · cited 3×
“14,15 The placebo effect was negligible in this study, in sharp contrast to the significant placebo responses that have been reported in most previous studies.”
InfluentialSurman, C. B. H., Monuteaux, M. C., Petty, C. R., Faraone, S. V., Spencer, T. J., Chu, N. F., & Biederman, J. (2010) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.09m05344pur · Cited by 54
Cited by
Mental health of prisoners: prevalence, adverse outcomes, and interventions
Fazel, S., Hayes, A. J., Bartellas, K., Clerici, M., & Trestman, R. (2016) · The Lancet Psychiatry · doi:10.1016/s2215-0366(16)30142-0 · Cited by 992
Young, S., Adamo, N., Ásgeirsdóttir, B. B., Branney, P., Beckett, M., Colley, W., Cubbin, S., Deeley, Q., Farrag, E., Gudjonsson, G., et al. (2020) · BMC Psychiatry · doi:10.1186/s12888-020-02707-9 · Cited by 610
Young, S., Moss, D., Sedgwick, O., Fridman, M., & Hodgkins, P. (2015) · Psychological Medicine · doi:10.1017/s0033291714000762 · Cited by 291
“Three studies (Young et al. 2009a; Ginsberg & Lindefors, 2012; Tidefors & Strand, 2012) were excluded as they used samples composed solely of participants who had ADHD, hence giving a prevalence rate of 100%.”
BackgroundMethodKonstenius, M., Jayaram‐Lindström, N., Guterstam, J., Beck, O., Philips, B., & Franck, J. (2014) · Addiction · doi:10.1111/add.12369 · Cited by 188
“The disproportionately high prevalence rate of ADHD and SUD in prison populations [2–5] is noteworthy, and represents a major public health problem and challenge to psychiatric and prison services globally.”
BackgroundInfluentialFredriksen, M., Halmøy, A., Faraone, S. V., & Haavik, J. (2013) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2012.07.016 · Cited by 173
Metadata
- Authors
- Ginsberg, Y., & Lindefors, N.
- Venue
- British Journal of Psychiatry
- Publisher
- Royal College of Psychiatrists
- Published
- 2012-01
- Volume
- 200
- Issue
- 1
- Pages
- 68-73
- ISSN
- 0007-1250 (ISSN-L)
- 1472-1465
- OpenAlex
- W1965366834
- Cited by
- 99
- References
- 11
- FWCI
- 3.94
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Methylphenidate treatment of adult male prison inmates with attention-deficit hyperactivity disorder: randomised double-blind placebo-controlled trial with open-label extension. https://app.cochat.ai/papers/10.1192/bjp.bp.111.092940
- The paper
- Ginsberg, Y., & Lindefors, N. (2012). Methylphenidate treatment of adult male prison inmates with attention-deficit hyperactivity disorder: randomised double-blind placebo-controlled trial with open-label extension. British Journal of Psychiatry. https://doi.org/10.1192/bjp.bp.111.092940
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.